A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers

Cancer Immunology, Immunotherapy

Volumn 52, Issue 10, 2003, Pages 608-616

  Ragupathi, Govind ^a   Koide, Fusataka ^a   Sathyan, Natarajan ^a   Kagan, Ella ^a   Spassova, Maria ^a   Bornmann, William ^a   Gregor, Polly ^a   Reis, Celso A ^b,c   Clausen, Henrik ^b   Danishefsky, Samuel J ^a   Livingston, Philip O ^a,d,e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF PORTO   (Portugal)

^d A Subsidiary of Lantheus Holdings   (United States)

^e Galenica Pharmaceuticals Incorporated   (United States)

Author keywords

Cancer vaccines; Carbohydrates; Conjugate vaccines; KLH; Polyvalent vaccines; Synthetic antigens

Indexed keywords

CANCER VACCINE; CYCLOPHOSPHAMIDE; GANGLIOSIDE GM2; GPI 0100; HEPTAVALENT VACCINE; IMMUNOLOGICAL ADJUVANT; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; MUCIN 1; POLYSORBATE 80; QS 21; SAPONIN; TUMOR ANTIGEN; TUMOR ANTIGEN GLOBO H; TUMOR ANTIGEN LEWIS Y; TUMOR ANTIGEN STN; TUMOR ANTIGEN TF; TUMOR ANTIGEN TN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL ACTIVITY; CELL SURFACE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; FREEZE DRYING; HELPER CELL; HUMAN; HUMAN CELL; IMMUNOGENICITY; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CA-15-3 ANTIGEN; CANCER VACCINES; DRUG EVALUATION, PRECLINICAL; FEMALE; GANGLIOSIDES; HEMOCYANIN; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LEWIS BLOOD-GROUP SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, GLANDULAR AND EPITHELIAL; PEPTIDE FRAGMENTS; SAPONINS; T-LYMPHOCYTES; VACCINATION; VACCINES, CONJUGATE;

EID: 0142106005     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0399-2     Document Type: Article

References (47)

1. Fung PYS, Madej M, Koganty RR, Longenecker BM (1990) Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 50:4308-4314
2. Singhal A, Fohn M, Hakomori S-I (1991) Induction of a α-N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active immunotherapy in mice. Cancer Res 51:1406-1411
3. Zhang S, Walberg LA, Helling F, Ragupathi G, Adluri S, Lloyd KO, Livingston PO (1996) Augmenting the immunogenicity of synthetic MUC-1 vaccines in mice. Cancer Res 55:3364-3368
4. Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB (1997) Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res 7:S155-S162
5. Zhang H, Zhang S, Cheung NK, Ragupathi G, Livingston PO (1998) Antibodies can eradicate cancer micrometastases. Cancer Res 58:2844-2849
6. Livingston PO, Wong GYC, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Helling, F, Ritter G, Oettgen HF, Old LJ (1994) Improved survival in AJCC stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 12:1036-1044
7. MacLean GD, Reddish MA, Koganty RR, Longenecker BM (1996) Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother 19:59-68
8. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trials E1694/S9512/C509801. J Clin Oncol 19:2370-2380
9. Ferrone S (2002) Tumor escape mechanisms. Semin Cancer Biol 12:1-86
10. Helling F, Shang Y, Calves M, Oettgen HF, Livingston PO (1994) Increased immunogenicity of GD3 conjugate vaccines: Comparison of various carrier proteins and selection of GD3-KLH for further testing. Cancer Res 54:197-203
11. Helling F, Zhang A, Shang A, Adluri S, Calves M, Koganty R, Longenecker BM, Oettgen HF, Livingston PO (1995) GM2-KLH conjugate vaccine: Increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 55:2783-2788
12. Kim S-K, Ragupathi G, Musselli C, Livingston PO (1999) Comparison of the effect of different immunological adjuvants on the antibody and T cell response to immunization with MUC1-KLH and GD3-KLH conjugate vaccines. Vaccine 18:597-603
13. Kim SK, Ragupathi G, Cappello S, Kagan E, Livingston PO (2000) Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine. 19:530-537
14. Ragupathi G, Cappello S, Yi SS, Canter D, Spassova M, Bornmann WG, Danishefsky SJ, Livingston PO (2002) Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines. Vaccine 20:1030-1038
15. Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, Lloyd KO, Livingston PO (1997) Selection of carbohydrate tumor antigens as targets for immune attack using immunohistochemistry: I. focus on gangliosides. Int J Cancer 73:42-49
16. Zhang S, Zhang HS, Cordon-Cardo C, Reuter VE, Singhal AK, Lloyd KO, Livingston PO (1997) Selection of tumor antigens as targets for immune attack using immunohistochemistry. II. blood group-related antigens. Int J Cancer 73:50-56
17. Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO (1998) Selection of tumor antigens as targets for immune attack using immunohistochemistry: III. protein antigens. Clin Cancer Res 4:2669-2676
18. Kensil CR, Patel U, Lennick M, Marciani D (1982) Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortx. J Immunol 12:91-96
19. Marciani DJ, Press JB, Reynolds RC, Pathak AK, Pathak V, Gundy LE, Farmer JT, Koratich MS, May RD (2000) Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 18:3141-3151
20. Krummel MF, Allison JP (1995) CD28 and CTLA-4 have opposing effects on the response of T-cells to stimulation. J Exp Med 182:459-465
21. Bilodeau MT, Park TK, Hu S, Randolph JT, Danishefsky SJ, Livingston PO, Zhang S (1995) Total synthesis of a human breast tumor associated antigen. J Amer Chem Soc 117:7840-7841
22. Ragupathi G, Slovin S, Adluri S, Sames D, Kim I-J, Kim HM, Spassova M, bornmann WG, Lloyd KO, Scher HI, Livingston PO, Danishefsky SJ (1999) A fully synthetic globo H carbohydrate vaccine induces a focused humoral response in prostate cancer patients: a proof of principle. Angewandte Chemie 38:563-566
23. Ragupathi G, Howard L, Cappello S, Koganty RR, Qiu D, Longenecker BM, Reddish MA, Lloyd KO, Livingston PO (1999) Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells. Cancer Immunol Immunother 48:1-8
24. Kuduk SD, Schwarz JB, Chen X-T, Glunz PW, Sames D, Ragupathi G, Livingston PO, Danishefsky SJ (1998) Synthetic and Immunological studies on clustered modes of Mucin related Tn and TF O-linked antigens: the Preparation of a glycopeptide based vaccine for clinical trials against prostate cancer. J Am Chem Soc 120:12474-12485
25. Wandall HH, Hassan H, Mirgorodskaya K, Kristensen AK, Roepstorff P, Bennett EP, Nielsen PA, Hollingsworth MA, Burchell J, Taylor-Papadimitriou J, Clausen H (1997) Substrate specificities of three members of the human UDP-N-acetyl-a-D-galactosamine: polypeptide N-Acetylgalactosaminyltransferase family, Ga1NAc-T1, -T2, and -T3. J Biol Chem 272:23503-23514
26. Bennett EP, Hassan H, Mandel U, Mirgorodskaya E, Roepstorff P, Burchell J, Taylor-Papadimitriou J, Hollingsworth MA, Merkx G, van Kessel AG, Eiberg H, Steffensen R, Clausen H (1998) Cloning of a human UDP-N-acetyl-α -D-Galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other Ga1NAc-transferases in complete O-glycosylation of the MUC1 tandem repeat. J Biol Chem 273:30472-481
27. Ragupathi G, Meyers M, Adluri S, Howard L, Musselli C, Livingston P O (2000) Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer 85: 659-666
28. Huntsberger DV, Leaverton PE (1970) Measurement data: II. tests for statistical significance. In: Huntsberger DV, Leaverton PE (eds) Statistical inference in the biomedical sciences. Allyn Bacon, Boston
29. Adluri S, Helling F, Calves MJ, Lloyd KO, Livingston PO (1995) Immunogenicity of synthetic TF- and STn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 41:185-192
30. Gilewski T, Adluri S, Zhang S, Ragupathi G, Houghton A, Norton L, Livingston PO (2000) Vaccination of high-risk breast cancer patients with Mucin-1 keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res 6:1693-1701
31. Y-protein conjugate vaccine: a phase 1 trial. Int J Cancer 87:79-85
32. Peters CC, Tenbergen-Meeks AM, Poolman JT, Beurret M, Zegers, BJM, Rijkers GT (1974) Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect Immun 59:3504-3510
33. Sarvas H, Makela O, Toivanen P, Toivanen A (1974) Effect of carrier preimmunization on the anti-hapten response in chicken. Scand J Immunol 3:455-60
34. 197. Infect Immun 39:233-238
35. Sarnaik S, Kaplan J, Schiffman G, Bryla D, Robbins JB, Schneerson R (1990) Studies on Pneumococcus vaccine alone or mixed with DTP and on Pneumococcus type 6B and Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in two- to five-year-old children with sickle cell anemia. Pediatr Infect Dis J 9:181-186
36. Barington T, Skettrup M, Juul L, Heilman C (1993) Non-epitope-specific suppression of antibody response to Haemophilus influenzae type b conjugate vaccine by preimmunization with vaccine components. Infect Immun 61:432-438
37. Barington T, Gyhrs A, Kristensen K, Heilmann C (1994) Opposite effect of actively and passively acquired immunity to the carrier on response of human infants to Haemophilus influenzae type b conjugate vaccine. Infect Immun 62: 9-14
38. Cross A, Artenstein A, Que J, Fredeking T, Furer E, Sadoff JC, Cryz SJ (1994) Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis 170:834-840
39. Insel RA (1995) Potential alterations in immunogenicity by combining or simultaneously administering vaccines components. In: Williams, JC, et al (eds) Combined vaccines and simultaneous administration: current issues and perspectives. Ann N Y Acad Sci 754:35-47
40. Molrine DC, George S, Tarbell N, Mauch P, Diller L, Neuberg D, Shamberger RC, Anderson EL, Phillips NR, Kinella K (1995) Antibody response to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease. Ann Intern Med 123:828-834
41. Kurika S (1996) Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine 14:1239-42
42. Fattom A, Cho YH, Chu C, Fuller S, Fries L, Naso, R (1999) Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 17: 126-33
43. Bass KK, Mastrangelo MJ (1998) Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 47:1-12
44. Van Elsas A, Hurwitz AA, Allison JP (1995) Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 182:459-465
45. Lee KM, Chuang E, Griffin M, Khattri R, Hong DK, Zhang W, Straus D, Samelson LE, Thompson CB, Bluestone JA (1998) Molecular basis of T cell inactivation by CTLA-4. Science 282:22263-2266
46. + regulatory T-cells in antitumor therapy reveals alternative pathways for suppression of auto reactive cytotoxic T lymphocyte responses. J Exp Med 194:823-832
47. Livingston PO, Adluri S, Helling F, Yao T-J, Kensil CR, Newman MJ, Marciani, D (1994) Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12:1275-1280